Arrowstreet Capital
RPRX icon

Arrowstreet Capital’s Royalty Pharma RPRX Stock Holding History

Arrowstreet Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
2,435,341
+424,943
+21% +$22.1M 0.06% 276
2026
Q1 		$96.4M Sell
2,010,398
-1,302,867
-39% -$57.1M 0.05% 316
2025
Q4 		$128M Buy
3,313,265
+31,091
+0.9% +$1.19M 0.08% 246
2025
Q3 		$116M Buy
3,282,174
+305,694
+10% +$11.1M 0.07% 248
2025
Q2 		$107M Buy
2,976,480
+1,615,706
+119% +$53.5M 0.08% 246
2025
Q1 		$42.4M Buy
1,360,774
+690,893
+103% +$21.9M 0.03% 404
2024
Q4 		$17.1M Sell
669,881
-720,342
-52% -$19.1M 0.01% 658
2024
Q3 		$39.3M Buy
1,390,223
+450,189
+48% +$12.5M 0.03% 382
2024
Q2 		$24.8M Buy
940,034
+57,288
+6% +$1.59M 0.02% 431
2024
Q1 		$26.8M Sell
882,746
-896,490
-50% -$26.4M 0.02% 441
2023
Q4 		$50M Sell
1,779,236
-174,006
-9% -$4.78M 0.05% 268
2023
Q3 		$53M Buy
1,953,242
+39,026
+2% +$1.16M 0.06% 240
2023
Q2 		$58.8M Sell
1,914,216
-41,909
-2% -$1.42M 0.07% 220
2023
Q1 		$70.5M Sell
1,956,125
-542,745
-22% -$20.1M 0.09% 210
2022
Q4 		$98.8M Buy
2,498,870
+577,444
+30% +$24.1M 0.14% 161
2022
Q3 		$77.2M Buy
1,921,426
+864,871
+82% +$36.9M 0.11% 174
2022
Q2 		$44.4M Buy
1,056,555
+464,078
+78% +$19M 0.06% 236
2022
Q1 		$23.1M Buy
+592,477
New +$23.3M 0.03% 376
2021
Q4 		– Sell
-59,330
Closed -$2.14M – 1682
2021
Q3 		$2.14M Buy
+59,330
New +$2.31M ﹤0.01% 1117
2021
Q2 		– Sell
-17,900
Closed -$781K – 2169
2021
Q1 		$781K Buy
+17,900
New +$849K ﹤0.01% 1872
2020
Q4 		– Sell
-294,481
Closed -$12.4M – 2502
2020
Q3 		$12.4M Buy
+294,481
New +$12.6M 0.02% 745

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arrowstreet Capital's RPRX Position: Q2 2026 in Review

Arrowstreet Capital increased its Royalty Pharma (RPRX) stake by 21% in Q2 2026, buying an estimated $22.1M and bringing the position to 2,435,341 shares worth $137M. The position accounts for 0.06% of the portfolio, ranked #276.

Arrowstreet Capital first reported a position in RPRX in Q3 2020 and has held it in 21 quarters since. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Arrowstreet Capital held 2,435,341 shares of Royalty Pharma worth $137M as of Q2 2026.
  • Arrowstreet Capital bought 424,943 Royalty Pharma shares in Q2 2026, an estimated $22.1M.
  • Royalty Pharma made up 0.06% of Arrowstreet Capital's portfolio in Q2 2026, its #276 holding.
  • Arrowstreet Capital first reported a position in Royalty Pharma in Q3 2020 and has held it in 21 quarters since.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.